Quantification of sodium thiosulphate protection on cisplatin-induced toxicities

Journal of Otolaryngology

Volumn 32, Issue 3, 2003, Pages 146-150

  Leitao, Darren J ^a   Blakley, Brian W ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b Department of Otolaryngology ^*  (Canada)

Author keywords

Auditory brainstem response (ABR); Chemotherapy; Cisplatin; Guinea pig; Ototoxicity; Sodium thiosulphate

Indexed keywords

CISPLATIN; SODIUM THIOSULFATE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUDITORY STIMULATION; AUDITORY THRESHOLD; BONE MARROW TOXICITY; BRAIN STEM RESPONSE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DOSE RESPONSE; DRUG FATALITY; EVOKED BRAIN STEM AUDITORY RESPONSE; GUINEA PIG; HEARING; LEUKOCYTE COUNT; MALE; MAXIMUM TOLERATED DOSE; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; OTOTOXICITY; PRIORITY JOURNAL; PROTECTION; SURVIVAL; UREA NITROGEN BLOOD LEVEL;

EID: 0041817737     PISSN: 03816605     EISSN: None     Source Type: Journal    
DOI: 10.2310/7070.2003.40406     Document Type: Article

References (16)

1. Forastiere A, Takasugi BJ, Baker SR, et al. High dose cisplatin in advanced head and neck cancer. Cancer Chemother Pharmacol 1987; 19:155-158.
2. Madasu R, Ruckenstein MJ, Leake F, et al. Ototoxic effects of supradose cisplatin with sodium thiosulfate neutralization in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 1997; 123:978-981.
3. Pfeifle CE, Howell SB, Felthouse RD, et al. High-dose cisplatin with sodium thiosulfate protection. J Clin Oncol 1985; 3:237-244.
4. Markman M, D'Acquisto R, Iannotti N, et al. Phase-1 trial of high-dose intravenous cis-platin with simultaneous intravenous sodium thiosulfate. J Cancer Res Clin Oncol 1991; 117:151-155.
5. Muidoon LL, Pagel MA, Kroll RA, et al. Delayed administration of sodium thiosulfate in animal models reduces platinum ototoxicity without reduction of antitumor activity. Clin Cancer Res 2000; 6:309-315.
6. Kaltenbach JA, Church MA, Blakley BW, et al. Comparison of five agents in protecting the cochlea against the ototoxic effect of cisplatin in the hamster. Otolaryngol Head Neck Surg 1997; 117:493-500.
7. Otto WC, Brown RD, Gage-White L, et al. Effects of cisplatin and thiosulfate upon auditory brainstem responses of guinea pigs. Hear Res 1988; 35:79-86.
8. Nagai N, Hotta K, Yamamura H, et al. Effects of sodium thiosulfate on the pharmacokinetics of unchanged cisplatin and on the distribution of platinum species in rat kidney: protective mechanism against cisplatin nephrotoxicity. Cancer Chemother Pharmacol 1995; 36:404-410.
9. Abe R, Akiyoshi T, Baba T. Inactivation of cisdiamminedichloroplatinum (II) in blood by sodium thiosulfate. Oncology 1990; 47:65-69.
10. Los G, Blommaert FA, Barton R, et al. Selective intra-arterial infusion of high-dose cisplatin in patients with advanced head and neck cancer results in high tumor platinum concentrations and cisplatin-DNA adduct formation. Cancer Chemother Pharmacol 1995; 37:150-154.
11. Dum N. Postnatal development of the auditory evoked brainstem potentials in the guinea pig. Acta Otolaryngol (Stockh) 1984; 97:63-68.
12. Nozawa I, Imamura S, Fujimori I, et al. Age-related alterations in the auditory brainstem responses and the compound action potentials in guinea pigs. Laryngoscope 1996; 106:1034-1039.
13. Weisman RA, Christen R, Los G, et al. Phase I trial of retinoic acid and cisplatinum for advanced squamous cell cancer of the head and neck based on experimental evidence of drug synergism. Otolaryngol Head Neck Surg 1998; 118:597-602.
14. Rybak LP, Whitworth C, Somani S. Application of antioxidants and other agents to prevent cisplatin ototoxicity. Laryngoscope 1999; 109:1740-1744.
15. Evans P, Halliwell B. Free radicals and hearing. Cause, consequence, and criteria. Ann N Y Acad Sci 1999; 884:19-20.
16. Rybak LP, Husain K, Whitworth C, Somani SM. Dose dependent protection by lipoic acid against cisplatin-induced ototoxicity in rats: antioxidant defense system. Toxicol Sci 1999; 47:195-202.